Chemical: Drug
somatropin recombinant

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for somatropin recombinant

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs1800012 NC_000017.10:g.48277749C=, NC_000017.10:g.48277749C>A, NC_000017.11:g.50200388C=, NC_000017.11:g.50200388C>A, NG_007400.1:g.6252G=, NG_007400.1:g.6252G>T, NM_000088.3:c.104-441G=, NM_000088.3:c.104-441G>T, XM_005257058.1:c.104-441G=, XM_005257058.1:c.104-441G>T, XM_005257058.3:c.104-441G=, XM_005257058.3:c.104-441G>T, XM_005257059.1:c.104-441G=, XM_005257059.1:c.104-441G>T, XM_005257059.3:c.104-441G=, XM_005257059.3:c.104-441G>T, XM_011524341.1:c.104-441G=, XM_011524341.1:c.104-441G>T, rs58312232, rs8179177
C > A
SNP
No VIP available CA VA
rs2069502 NC_000012.11:g.58144665C>T, NC_000012.12:g.57750882C>T, NG_007484.2:g.6500G>A, NM_000075.2:c.522+41G>A, NM_000075.3:c.522+41G>A, XM_005268560.1:c.300+41G>A, XR_245887.1:n.631-211G>A, rs3211616, rs386556250, rs58413455
C > T
SNP
No VIP available CA VA
rs2270777 NC_000012.11:g.58145156C>T, NC_000012.12:g.57751373C>T, NG_007484.2:g.6009G>A, NM_000075.2:c.219-31G>A, NM_000075.3:c.219-31G>A, XM_005268560.1:c.-4-31G>A, XR_245887.1:n.585-31G>A, rs116993627, rs3211611
C > G
C > T
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • GH
  • GH-N
  • Growth hormone
  • Growth hormone 1
  • Pituitary growth hormone
  • Somatotropin precursor
  • Somatropin
Trade Names
  • BioTropin (Biotech General)
  • Genotropin (Pfizer)
  • Humatrope (Eli Lilly)
  • Norditropin (Novo Nordisk)
  • Nutropin (Genentech Inc.)
  • NutropinAQ (Genentech Inc.)
  • Protropin (Genentech Inc.)
  • Saizen (Serono SA)
  • Serostim
  • Serostim (Serono SA)
  • Tev-Tropin (GATE)
Brand Mixture Names

PharmGKB Accession Id

PA451446

Type(s):

Drug

Description

Recombinant human growth hormone (somatotropin) 191 residues, MW 22.1 kD, synthesized in E. coli

Source: Drug Bank

Indication

For treatment of dwarfism, acromegaly and prevention of HIV-induced weight loss

Source: Drug Bank

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

hGH binds to the human growth hormone receptor (GHR). Upon binding, hGH causes dimerization of GHR, activation of the GHR-associated JAK2 tyrosine kinase, and tyrosyl phosphorylation of both JAK2 and GHR. These events recruit and/or activate a variety of signaling molecules, including MAP kinases, insulin receptor substrates, phosphatidylinositol 3' phosphate kinase, diacylglycerol, protein kinase C, intracellular calcium, and Stat transcription factors. These signaling molecules contribute to the GH-induced changes in enzymatic activity, transport function, and gene expression that ultimately culminate in changes in growth and metabolism.

Source: Drug Bank

Pharmacology

Used in the treatment of dwarfism and growth failure, growth hormone (hGH) stimulates skeletal growth in pediatric patients with growth failure due to a lack of adequate secretion of endogenous GH. Skeletal growth is accomplished at the epiphyseal plates at the ends of a growing bone. Growth and metabolism of epiphyseal plate cells are directly stimulated by GH and one of its mediators, IGF-I (insulin-like growth factor).

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Clearance

Source: Drug Bank

Route of Elimination

Although calcium excretion in the urine is increased, there is a simultaneous increase in calcium absorption from the intestine. Somatropin stimulates the synthesis of chondroitin sulfate and collagen, and increases the urinary excretion of hydroxyproline.

Source: Drug Bank

Chemical Properties

Chemical Formula

C990H1532N262O300S7

Source: Drug Bank

Canonical SMILES

Not Available

Source: Drug Bank

Average Molecular Weight

22129.0000

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

EvidenceGene
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CDK4
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
COL1A1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GHR
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
IGF1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
IGFBP3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SHOX

Drug Targets

Gene Description
GHR (source: Drug Bank )
PRLR (source: Drug Bank )

Drug Interactions

Interaction Description
acarbose - somatropin recombinant Somatropin may antagonize the hypoglycemic effect of acarbose. Monitor for changes in fasting and postprandial blood sugars. (source: Drug Bank )
chlorpropamide - somatropin recombinant Somatropin may antagonize the hypoglycemic effect of chlorpropamide. Monitor for changes in fasting and postprandial blood sugars. (source: Drug Bank )
exenatide - somatropin recombinant Somatropin may antagonize the hypoglycemic effect of exenatide. Monitor for changes in fasting and postprandial blood sugars. (source: Drug Bank )
glibenclamide - somatropin recombinant Somatropin may antagonize the hypoglycemic effect of glibenclamide. Monitor for changes in fasting and postprandial blood sugars. (source: Drug Bank )
gliclazide - somatropin recombinant Somatropin may antagonize the hypoglycemic effect of gliclazide. Monitor for changes in fasting and postprandial blood sugars. (source: Drug Bank )
glimepiride - somatropin recombinant Somatropin may antagonize the hypoglycemic effect of glimepiride. Monitor for changes in fasting and postprandial blood sugars. (source: Drug Bank )
glipizide - somatropin recombinant Somatropin may antagonize the hypoglycemic effect of glipizide. Monitor for changes in fasting and postprandial blood sugars. (source: Drug Bank )
insulin-aspart - somatropin recombinant Somatropin may antagonize the hypoglycemic effect of insulin aspart. Monitor for changes in fasting and postprandial blood sugars. (source: Drug Bank )
insulin-detemir - somatropin recombinant Somatropin may antagonize the hypoglycemic effect of insulin detemir. Monitor for changes in fasting and postprandial blood sugars. (source: Drug Bank )
insulin-glargine - somatropin recombinant Somatropin may antagonize the hypoglycemic effect of insulin glargine. Monitor for changes in fasting and postprandial blood sugars. (source: Drug Bank )
insulin-glargine - somatropin recombinant Somatropin may antagonize the hypoglycemic effect of insulin glargine. Monitor for changes in fasting and postprandial blood sugars. (source: Drug Bank )
insulin-glulisine - somatropin recombinant Somatropin may antagonize the hypoglycemic effect of insulin glulisine. Monitor for changes in fasting and postprandial blood sugars. (source: Drug Bank )
metformin - somatropin recombinant Somatropin may antagonize the hypoglycemic effect of metformin. Monitor for changes in fasting and postprandial blood sugars. (source: Drug Bank )
miglitol - somatropin recombinant Somatropin may antagonize the hypoglycemic effect of miglitol. Monitor for changes in fasting and postprandial blood sugars. (source: Drug Bank )
nateglinide - somatropin recombinant Somatropin may antagonize the hypoglycemic effect of nateglinide. Monitor for changes in fasting and postprandial blood sugars. (source: Drug Bank )
pioglitazone - somatropin recombinant Somatropin may antagonize the hypoglycemic effect of pioglitazone. Monitor for changes in fasting and postprandial blood sugars. (source: Drug Bank )
repaglinide - somatropin recombinant Somatropin may antagonize the hypoglycemic effect of repaglinide. Monitor for changes in fasting and postprandial blood sugars. (source: Drug Bank )
rosiglitazone - somatropin recombinant Somatropin may antagonize the hypoglycemic effect of rosiglitazone. Monitor for changes in fasting and postprandial blood sugars. (source: Drug Bank )
sitagliptin - somatropin recombinant Somatropin may antagonize the hypoglycemic effect of sitagliptin. Monitor for changes in fasting and postprandial blood sugars. (source: Drug Bank )
tolazamide - somatropin recombinant Somatropin may antagonize the hypoglycemic effect of Tolazamide. Dose adjustments of Tolazamide may be required. (source: Drug Bank )
tolbutamide - somatropin recombinant Somatropin may antagonize the hypoglycemic effect of Tolbutamide. Dose adjustments of Tolbutamide may be required. (source: Drug Bank )
tolbutamide - somatropin recombinant Somatropin may antagonize the hypoglycemic effect of Tolbutamide. Dose adjustments of Tolbutamide may be required. (source: Drug Bank )

Curated Information ?

Publications related to somatropin recombinant: 8

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Height outcome of short children with hypochondroplasia after recombinant human growth hormone treatment: a meta-analysis. Pharmacogenomics. 2015. Massart Francesco, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Height outcome of the recombinant human growth hormone treatment in patients with SHOX gene haploinsufficiency: a meta-analysis. Pharmacogenomics. 2013. Massart Francesco, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenomics of insulin-like growth factor-I generation during GH treatment in children with GH deficiency or Turner syndrome. The pharmacogenomics journal. 2013. Stevens A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Additive effect of GHRd3 and COLIA1 polymorphisms on the GH-substitution dose in GH-deficient adults. Pharmacogenomics. 2011. Hartleb Silke, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Growth hormone pharmacogenetics: the interactive effect of a microsatellite in the IGF1 promoter region with the GHR-exon 3 and -202 A/C IGFBP3 variants on treatment outcomes of children with severe GH deficiency. The pharmacogenomics journal. 2011. Costalonga E F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults. Pharmacogenomics. 2009. Meyer Silke, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of COLIA1 Sp1 polymorphism with the effect of subcutaneously injected recombinant hGH in GH-deficient adults. Pharmacogenomics. 2008. Meyer Silke, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nature genetics. 2004. Dos Santos Christine, et al. PubMed

LinkOuts

GenBank:
AF374232
Web Resource:
Wikipedia
UniProtKB:
P58756
National Drug Code Directory:
0169-7704-21
DrugBank:
DB00052
Drugs Product Database (DPD):
2243079
Therapeutic Targets Database:
DAP001054
FDA Drug Label at DailyMed:
1058e17c-9261-459c-a3e6-fae38d196c14

Clinical Trials

These are trials that mention somatropin recombinant and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.